VTX-2337: Phase I data

A dose-escalation, U.S. Phase I trial in 33 patients with advanced solid tumors or lymphoma showed that 0.1-3.9 mg/m 2 doses of subcutaneous VTX-2337 on days 1, 8 and 15 of a 28-day cycle for 2 cycles...